Latest Derivatives News

Lunnon Metals has announced a maiden Mineral Resource Estimate for its Hustler gold deposit, adding 30,200 ounces to its portfolio and setting the stage for potential open pit mining alongside the nearby Lady Herial operation.

Metal Bank reports exceptional gold recovery results from its Seven Leaders Prospect near Kalgoorlie, highlighting a 72.5% gravity recovery and over 99% leaching efficiency, underpinning its near-term production ambitions.

Peak Processing Limited has renewed and expanded its manufacturing agreement with Electric Brands, securing an expected annual production of approximately 1.4 million Sweet Justice cannabis beverage units. This deal reinforces Peak’s position in North America’s regulated cannabis beverage market and supports growth in Canada and the US.

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Astron Limited has released updated Mineral Resource and Ore Reserve estimates for its Donald Project, highlighting increased production forecasts for critical heavy rare earth elements. The project remains shovel ready, backed by comprehensive feasibility studies and regulatory approvals.

Excelsior Capital Limited reported a $2.08 million loss for the half-year ending December 2025 as it moves to wind up operations, yet declared a substantial fully franked interim dividend.

Investigator Silver Limited’s Definitive Feasibility Study confirms the Paris Silver Project as a high-margin, low-risk development with rapid payback and modest funding needs. The study outlines a conventional open-pit mine in South Australia, poised for near-term production with robust financial metrics.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Harvest Technology Group’s half-year report reveals a 50% revenue decline and a widening net loss, offset by a $6 million funding facility and strategic partnerships.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

Change Financial has reported a strong first half for FY26 with record revenue growth and its first-ever half-year profit, underpinned by expanding recurring revenues and operational efficiencies.